Prime Medicine Posts $39M Q3 Operating Loss Days After $125M Raise
PRME sits 46% above its 52-week low of $2.67.
Summary
Prime Medicine reported a Q3 loss from operations of $39.9 million and a net loss of $39.0 million, with operating expenses of $44.1 million. EPS came in at -$0.22. The burn lands just two days after the company priced a $125 million common stock offering at $3.50 a share for 35,714,286 shares, and follows an 8-K disclosing roughly $61.2 million of unrestricted cash at September 30. The offering has since closed, with the underwriters fully exercising their option to purchase additional shares, bringing the total raised to $143.7 million and extending the company's cash runway through 2027. The company entered the quarter with a going concern warning and has been funding a pipeline that includes PM647 (FDA IND clearance in September) and PM577a (first patient dosed in October). The loss itself is consistent with a clinical-stage biotech spending through its programs; the key question is how far the new capital extends operations.
At the time of this announcement, PRME was trading at $3.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $705.6M. The 52-week trading range was $2.67 to $5.91. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.